Last reviewed · How we verify
NCT05522205
Regulated Cannabis Access in Basel
NA trial testing Regulated cannabis access in pharmacies in Cannabis Use Disorder in 374 participants. Participants enrolled and being followed up; not accepting new ones.
31 July 2025
Quick facts
| Lead sponsor | Health Department of the Canton of Basel-Stadt |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 374 |
| Start date | 31 January 2023 |
| Primary completion | 31 July 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Regulated cannabis access in pharmacies
Conditions studied
- Cannabis Use Disorder — all drugs for Cannabis Use Disorder →
- Mental Health Disorder — all drugs for Mental Health Disorder →
- Physical Illness — all drugs for Physical Illness →
Sponsor
Health Department of the Canton of Basel-Stadt
Who can join
18 and older, any sex, with Cannabis Use Disorder or Mental Health Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effects of cannabis regulation in Switzerland: Study protocol of a randomized controlled trial.
Baltes-Flueckiger L, Steinauer R, Meyer M, Vogel M, et al · · 2023 · cited 6× · PMID 37032954 · DOI 10.3389/fpsyt.2023.1139325 -
Effects of legal access versus illegal market cannabis on use and mental health: A randomized controlled trial.
Baltes-Flueckiger L, Steinauer R, Meyer M, Guessoum A, et al · · 2025 · cited 3× · PMID 40289676 · DOI 10.1111/add.70080 -
Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis
Mosandl C, Baltes-Flückiger L, Kronschnabel J, Meyer M, et al · · 2024
Verify or expand the search:
- PubMed search for NCT05522205
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cannabis Use Disorder
Currently open trials in the same condition.
- NCT07523633 — Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder · Phase 2 · recruiting
- NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
- NCT07218471 — Cannabis Reduction and Functional Outcomes · NA · recruiting
- NCT07184983 — RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative · NA · recruiting
- NCT06883162 — Cannabis-Tobacco Co-Use Treatment Study · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05522205 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Health Department of the Canton of Basel-Stadt
- Last refreshed: 2 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05522205.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing